Andrew Fleming

87 timestamped statements across 3 collections — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Liver Tumors (Hepatoblastoma/HCC) · guest expert

Featured diaries

▶ Ep 8 · 7:10
Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning.
quote · Hepatoblastoma
▶ Ep 10 · 7:10
Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning.
quote · Liver Tumors (Hepatoblastoma/HCC)
▶ Ep 10 · 7:10
Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning.
quote · Liver Tumors (Hepatoblastoma/HCC)
▶ Ep 8 · 8:06
I think again, just kind of the biggest takeaway is there is no threshold for disease burden that precludes you from aggressively trying to achieve no evidence of disease uh in children with hepatblastoma.
quote · Hepatoblastoma
▶ Ep 3 · 4:30
Our group takes a fairly aggressive approach to pulmonary metastasectomy for these patients, including bilateral uh reoperative pulmonary resections if necessary.
quote · Metastatic Disease
▶ Ep 3 · 5:30
On logistic regression for three-year mortality, uh only achieving no evidence of disease was associated with a significant decrease in patient mortality.
quote · Metastatic Disease

Nothing matches these filters — clear the search or widen the filters.

Hepatoblastoma 29 entries

BOB Ped Surg 2023 - Andrew Fleming, AAP - Presentation

▶ Ep 6 · 0:00
epidemiological Hepatoblastoma is the most common pediatric liver cancer ↗
▶ Ep 6 · 0:30
clinical The number of contiguous hepatic sections uninvolved by tumor can be used radiographically to determine the pre-treatment extent of disease, making the PRETEXT group ↗
▶ Ep 6 · 1:00
guideline PRETEXT group in combination with presence/absence of metastatic disease, alpha fetoprotein at diagnosis, PRETEXT modifiers, patient age and resectability at diagnosis can be used to risk stratify patients according to the AHEAD 1531 clinical trial ↗
▶ Ep 6 · 1:30
quote Complete surgical resection has been determined uh to be necessary for patient survival. ↗
▶ Ep 6 · 1:30
clinical Complete surgical resection has been determined to be necessary for patient survival ↗
▶ Ep 6 · 1:45
clinical Cisplatin based chemotherapies have improved rates of resectability and subsequently survival for hepatoblastoma patients ↗
▶ Ep 6 · 2:00
epidemiological The reported survival benefits of pulmonary metastasectomy for hepatoblastoma have varied in the literature ↗
▶ Ep 6 · 3:00
quote no evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging. ↗
▶ Ep 6 · 3:00
clinical No evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging ↗
▶ Ep 6 · 4:00
epidemiological Among 50 patients included for analysis, 24 were determined to be high risk ↗
▶ Ep 6 · 4:15
clinical All patients received chemotherapy and 41 patients were successfully able to be rendered no evidence of disease status ↗
▶ Ep 6 · 4:30
quote Our group takes a fairly aggressive approach to pulmonary metastasectomy for these patients, including bilateral uh reoperative pulmonary resections if necessary. ↗
▶ Ep 6 · 4:30
clinical 14 patients underwent a total of 31 pulmonary procedures, having a median of four nodules resected per patient ↗
▶ Ep 6 · 5:00
clinical Median of three nodules per patient contained pathologically confirmed viable hepatoblastoma, confirming a high degree of concordance between radiographic evidence of disease and pathological confirmation of disease ↗
▶ Ep 6 · 5:30
clinical On logistic regression for three-year mortality, only achieving no evidence of disease was associated with a significant decrease in patient mortality ↗
▶ Ep 6 · 5:30
quote On logistic regression for three-year mortality, uh only achieving no evidence of disease was associated with a significant decrease in patient mortality. ↗
▶ Ep 6 · 6:00
clinical The overall survival of the entire cohort is quite high ↗
▶ Ep 6 · 6:15
clinical The event-free survival is lower than overall survival due to relapse events after achieving no evidence of disease ↗
▶ Ep 6 · 6:30
clinical The overall survival and event-free survival of the group in whom we were unable to render them no evidence of disease is significantly lower, with no patients in these cohorts surviving past two years ↗
▶ Ep 6 · 6:45
quote no patients in these cohorts uh surviving past two years. ↗
▶ Ep 6 · 7:00
clinical The overall survival is similar between high risk and not high risk patients who were able to be rendered no evidence of disease status ↗
▶ Ep 6 · 7:15
clinical The event-free survival remains significantly lower for the high-risk no evidence of disease group due to five high-risk patients who relapsed ↗
▶ Ep 6 · 7:30
clinical Three of five high-risk patients who relapsed were successfully salvaged using a combination of chemotherapy and further pulmonary resections ↗
▶ Ep 6 · 7:45
clinical Repeated pulmonary metastasectomy and/or complex local control strategies to obtain no evidence of disease benefit high risk patients ↗
▶ Ep 6 · 7:45
clinical No evidence of disease status is necessary for survival in patients with hepatoblastoma ↗

Journal of Pediatric Article Review: June 2023, AAP Issue

▶ Ep 8 · 7:10
clinical Once NED status was achieved, 10-year overall survival among high-risk hepatoblastoma patients was similar to patients who were not high-risk ↗
▶ Ep 8 · 7:10
quote Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning. ↗
▶ Ep 8 · 8:06
opinion There is no threshold for disease burden that precludes aggressive pursuit of no-evidence-of-disease status in children with hepatoblastoma ↗
▶ Ep 8 · 8:06
quote I think again, just kind of the biggest takeaway is there is no threshold for disease burden that precludes you from aggressively trying to achieve no evidence of disease uh in children with hepatblastoma. ↗
Liver Tumors (Hepatoblastoma/HCC) 33 entries

BOB Ped Surg 2023 - Andrew Fleming, AAP - Presentation

▶ Ep 8 · 0:00
epidemiological Hepatoblastoma is the most common pediatric liver cancer ↗
▶ Ep 8 · 0:30
clinical The number of contiguous hepatic sections uninvolved by tumor can be used radiographically to determine the pre-treatment extent of disease, making the PRETEXT group ↗
▶ Ep 8 · 1:00
guideline PRETEXT group in combination with presence/absence of metastatic disease, alpha fetoprotein at diagnosis, PRETEXT modifiers, patient age and resectability at diagnosis can be used to risk stratify patients according to the AHEAD 1531 clinical trial ↗
▶ Ep 8 · 1:30
quote Complete surgical resection has been determined uh to be necessary for patient survival. ↗
▶ Ep 8 · 1:30
clinical Complete surgical resection has been determined to be necessary for patient survival ↗
▶ Ep 8 · 1:45
clinical Cisplatin based chemotherapies have improved rates of resectability and subsequently survival for hepatoblastoma patients ↗
▶ Ep 8 · 2:00
epidemiological The reported survival benefits of pulmonary metastasectomy for hepatoblastoma have varied in the literature ↗
▶ Ep 8 · 3:00
quote no evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging. ↗
▶ Ep 8 · 3:00
clinical No evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging ↗
▶ Ep 8 · 4:00
epidemiological Among 50 patients included for analysis, 24 were determined to be high risk ↗
▶ Ep 8 · 4:15
clinical All patients received chemotherapy and 41 patients were successfully able to be rendered no evidence of disease status ↗
▶ Ep 8 · 4:30
quote Our group takes a fairly aggressive approach to pulmonary metastasectomy for these patients, including bilateral uh reoperative pulmonary resections if necessary. ↗
▶ Ep 8 · 4:30
clinical 14 patients underwent a total of 31 pulmonary procedures, having a median of four nodules resected per patient ↗
▶ Ep 8 · 5:00
clinical Median of three nodules per patient contained pathologically confirmed viable hepatoblastoma, confirming a high degree of concordance between radiographic evidence of disease and pathological confirmation of disease ↗
▶ Ep 8 · 5:30
clinical On logistic regression for three-year mortality, only achieving no evidence of disease was associated with a significant decrease in patient mortality ↗
▶ Ep 8 · 5:30
quote On logistic regression for three-year mortality, uh only achieving no evidence of disease was associated with a significant decrease in patient mortality. ↗
▶ Ep 8 · 6:00
clinical The overall survival of the entire cohort is quite high ↗
▶ Ep 8 · 6:15
clinical The event-free survival is lower than overall survival due to relapse events after achieving no evidence of disease ↗
▶ Ep 8 · 6:30
clinical The overall survival and event-free survival of the group in whom we were unable to render them no evidence of disease is significantly lower, with no patients in these cohorts surviving past two years ↗
▶ Ep 8 · 6:45
quote no patients in these cohorts uh surviving past two years. ↗
▶ Ep 8 · 7:00
clinical The overall survival is similar between high risk and not high risk patients who were able to be rendered no evidence of disease status ↗
▶ Ep 8 · 7:15
clinical The event-free survival remains significantly lower for the high-risk no evidence of disease group due to five high-risk patients who relapsed ↗
▶ Ep 8 · 7:30
clinical Three of five high-risk patients who relapsed were successfully salvaged using a combination of chemotherapy and further pulmonary resections ↗
▶ Ep 8 · 7:45
clinical No evidence of disease status is necessary for survival in patients with hepatoblastoma ↗
▶ Ep 8 · 7:45
clinical Repeated pulmonary metastasectomy and/or complex local control strategies to obtain no evidence of disease benefit high risk patients ↗

Journal of Pediatric Article Review: June 2023, AAP Issue

▶ Ep 10 · 7:10
quote Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning. ↗
▶ Ep 10 · 7:10
clinical Once NED status was achieved, 10-year overall survival among high-risk hepatoblastoma patients was similar to patients who were not high-risk ↗
▶ Ep 10 · 7:10
quote Once no evidence of disease status was achieved, the 10 year overall survival. Among patients that were high risk from the get-go was actually similar to patients that were not high risk, which I think again kind of emphasizes that if you are able to get children to that point, they can have long-term survival despite being stratified into a very high-risk group from the beginning. ↗
▶ Ep 10 · 7:10
clinical Once NED status was achieved, 10-year overall survival among high-risk hepatoblastoma patients was similar to patients who were not high-risk ↗
▶ Ep 10 · 8:06
opinion There is no threshold for disease burden that precludes aggressive pursuit of no-evidence-of-disease status in children with hepatoblastoma ↗
▶ Ep 10 · 8:06
quote I think again, just kind of the biggest takeaway is there is no threshold for disease burden that precludes you from aggressively trying to achieve no evidence of disease uh in children with hepatblastoma. ↗
▶ Ep 10 · 8:06
opinion There is no threshold for disease burden that precludes aggressive pursuit of no-evidence-of-disease status in children with hepatoblastoma ↗
▶ Ep 10 · 8:06
quote I think again, just kind of the biggest takeaway is there is no threshold for disease burden that precludes you from aggressively trying to achieve no evidence of disease uh in children with hepatblastoma. ↗
Metastatic Disease 25 entries

BOB Ped Surg 2023 - Andrew Fleming, AAP - Presentation

▶ Ep 3 · 0:00
epidemiological Hepatoblastoma is the most common pediatric liver cancer ↗
▶ Ep 3 · 0:30
clinical The number of contiguous hepatic sections uninvolved by tumor can be used radiographically to determine the pre-treatment extent of disease, making the PRETEXT group ↗
▶ Ep 3 · 1:00
guideline PRETEXT group in combination with presence/absence of metastatic disease, alpha fetoprotein at diagnosis, PRETEXT modifiers, patient age and resectability at diagnosis can be used to risk stratify patients according to the AHEAD 1531 clinical trial ↗
▶ Ep 3 · 1:30
quote Complete surgical resection has been determined uh to be necessary for patient survival. ↗
▶ Ep 3 · 1:30
clinical Complete surgical resection has been determined to be necessary for patient survival ↗
▶ Ep 3 · 1:45
clinical Cisplatin based chemotherapies have improved rates of resectability and subsequently survival for hepatoblastoma patients ↗
▶ Ep 3 · 2:00
epidemiological The reported survival benefits of pulmonary metastasectomy for hepatoblastoma have varied in the literature ↗
▶ Ep 3 · 3:00
quote no evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging. ↗
▶ Ep 3 · 3:00
clinical No evidence of disease is defined as a normal AFP and the absence of detectable radiographic disease on interval surveillance imaging ↗
▶ Ep 3 · 4:00
epidemiological Among 50 patients included for analysis, 24 were determined to be high risk ↗
▶ Ep 3 · 4:15
clinical All patients received chemotherapy and 41 patients were successfully able to be rendered no evidence of disease status ↗
▶ Ep 3 · 4:30
quote Our group takes a fairly aggressive approach to pulmonary metastasectomy for these patients, including bilateral uh reoperative pulmonary resections if necessary. ↗
▶ Ep 3 · 4:30
clinical 14 patients underwent a total of 31 pulmonary procedures, having a median of four nodules resected per patient ↗
▶ Ep 3 · 5:00
clinical Median of three nodules per patient contained pathologically confirmed viable hepatoblastoma, confirming a high degree of concordance between radiographic evidence of disease and pathological confirmation of disease ↗
▶ Ep 3 · 5:30
quote On logistic regression for three-year mortality, uh only achieving no evidence of disease was associated with a significant decrease in patient mortality. ↗
▶ Ep 3 · 5:30
clinical On logistic regression for three-year mortality, only achieving no evidence of disease was associated with a significant decrease in patient mortality ↗
▶ Ep 3 · 6:00
clinical The overall survival of the entire cohort is quite high ↗
▶ Ep 3 · 6:15
clinical The event-free survival is lower than overall survival due to relapse events after achieving no evidence of disease ↗
▶ Ep 3 · 6:30
clinical The overall survival and event-free survival of the group in whom we were unable to render them no evidence of disease is significantly lower, with no patients in these cohorts surviving past two years ↗
▶ Ep 3 · 6:45
quote no patients in these cohorts uh surviving past two years. ↗
▶ Ep 3 · 7:00
clinical The overall survival is similar between high risk and not high risk patients who were able to be rendered no evidence of disease status ↗
▶ Ep 3 · 7:15
clinical The event-free survival remains significantly lower for the high-risk no evidence of disease group due to five high-risk patients who relapsed ↗
▶ Ep 3 · 7:30
clinical Three of five high-risk patients who relapsed were successfully salvaged using a combination of chemotherapy and further pulmonary resections ↗
▶ Ep 3 · 7:45
clinical No evidence of disease status is necessary for survival in patients with hepatoblastoma ↗
▶ Ep 3 · 7:45
clinical Repeated pulmonary metastasectomy and/or complex local control strategies to obtain no evidence of disease benefit high risk patients ↗